ORIGINAL RESEARCH

QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System

Neha Mantri, MD; Meng Lu, MD, MS; Jonathan G. Zaroff, MD; Neil Risch, PhD; Thomas Hoffmann, PhD; Akinyemi Oni-Orisan, PhD; Catherine Lee, PhD; Eric Jorgenson, PhD; Carlos Iribarren, MD, MPH, PhD

BACKGROUND: Long QT has been associated with ventricular dysrhythmias, cardiovascular disease (CVD) mortality, and sudden cardiac death. However, no studies to date have investigated the dynamics of within-person QT change over time in relation to risk of incident CVD and all-cause mortality in a real-world setting.

METHODS AND RESULTS: A cohort study among members of an integrated health care delivery system in Northern California including 61,455 people (mean age, 62 years; 60% women, 42% non-White) with 3 or more ECGs (baseline in 2005–2009; mean±SD follow-up time, 7.6±2.6 years). In fully adjusted models, tertile 3 versus tertile 1 of average QT corrected (using the Fridericia correction) was associated with cardiac arrest (hazard ratio [HR], 1.66), heart failure (HR, 1.62), ventricular dysrhythmias (HR, 1.56), all CVD (HR, 1.31), ischemic heart disease (HR, 1.28), total stroke (HR, 1.18), and all-cause mortality (HR, 1.24). Tertile 3 versus tertile 2 of the QT corrected linear slope was associated with cardiac arrest (HR, 1.22), ventricular dysrhythmias (HR, 1.12), and all-cause mortality (HR, 1.09). Tertile 3 versus tertile 1 of the QT corrected root mean squared error was associated with ventricular dysrhythmias (HR, 1.34), heart failure (HR, 1.28), all-cause mortality (HR, 1.20), all CVD (HR, 1.14), total stroke (HR, 1.08), and ischemic heart disease (HR, 1.07).

CONCLUSIONS: Our results demonstrate improved predictive ability for CVD outcomes using longitudinal information from serial ECGs. Long-term average QT corrected was more strongly associated with CVD outcomes than the linear slope or the root mean squared error. This new evidence is clinically relevant because ECGs are frequently used, noninvasive, and inexpensive.

Key Words: epidemiology • long QT • QT interval • short QT syndrome

The QT interval is the time from the beginning of the Q wave until the end of the T wave in the ECG and is a noninvasive biomarker of ventricular repolarization. An abnormally prolonged QT interval (>450 ms in men and >460 ms in women) can lead to early afterdepolarizations and premature action potentials, which can in turn result in ventricular arrhythmias and sudden cardiac death.1–6 Congenital but rare forms of long-QT syndrome are well described.7 Acquired forms of long-QT syndrome are more common and typically induced by cardiac and noncardiac medications.

The association of the QT interval with cardiovascular disease (CVD) outcomes, including sudden cardiac death, is well established.9 However, limitations of the prior literature on the prognostic value of the QT interval include reliance on selected clinical populations including patients with myocardial infarction,6,9,10 chronic ischemic heart disease,11–13 heart failure,11–13 end-stage renal disease,14 type 2 diabetes,15 hypertension,16 rheumatoid arthritis,17 hypertrophic cardiomyopathy,18 atrial fibrillation,19 and chronic obstructive pulmonary disease,20 and the fact that studies relied on a QT interval measure at a single point in time.21–29 Thus, the relevance of
within-person QT dynamics (long-term average, linear change, and fluctuation over time) for CVD risk prediction in a real-world ambulatory population is unknown.

The purpose of the present study was therefore to examine the association of QT interval dynamics with incident CVD outcomes and all-cause mortality in a large and ethnically diverse population-based sample. The strengths of our study include not only assessment of a nonselected population, but also ascertainment of multiple QT corrected (QTc) measurements and covariates over time.

CLINICAL PERSPECTIVE

What Is New?
• Our results demonstrate that within-person QT corrected (QTc) dynamic measures (long-term average, linear change, and fluctuation over time) are independently associated with cardiovascular outcomes.
• Long-term average QTc was the strongest predictor of ischemic heart disease, cardiac arrest, ventricular dysrhythmias, and the combined cardiovascular disease outcome, whereas the average QTc and the last QTc measure were equally predictive of heart failure, total stroke, and all-cause mortality.

What Are the Clinical Implications?
• Valuable information can be obtained from serial QTc measures that outperform a QTc measure at a single point in time.
• Given that ECG testing is ubiquitous, routine, inexpensive, and frequently performed serially, an improved understanding of the predictive ability of QTc change and variability over time may help clinicians to risk stratify patients.

Nonstandard Abbreviations and Acronyms

Nonstandard Abbreviations and Acronyms

IHD ischemic heart disease
KPNC Kaiser Permanente of Northern California
QTc QT corrected
RMSE root mean squared error

The purpose of the present study was therefore to examine the association of QT interval dynamics with incident CVD outcomes and all-cause mortality in a large and ethnically diverse population-based sample. The strengths of our study include not only assessment of a nonselected population, but also ascertainment of multiple QT corrected (QTc) measurements and covariates over time.

METHODS

Data are available on request from the authors. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Population and Study Design
Kaiser Permanente of Northern California (KPNC) is an integrated health care delivery system serving ≈4.5 million members. The membership is stable, with <10% turnover annually overall and <3% to 5% among members aged 65 years and older and/or who have a chronic illness. The program delivers comprehensive inpatient and outpatient care to its members and captures many aspects of its care in multiple comprehensive clinical and administrative databases. KPNC’s population is ethnically and socioeconomically diverse, and is broadly representative of the Northern California population.

We retrospectively identified all of the 12-lead surface ECGs that were performed on KPNC members as part of routine outpatient or inpatient medical care in the period spanning between January 1, 2005 and December 31, 2009. A total of 3 149 872 ECG tracings were identified among 1 145 665 subjects. ECG tracings with evidence of pacemakers (n=71 947), with QTc (n=8677) or heart rate (n=13 214) out of physiological range (ie, QTc <200 or >800 ms and heart rate <40 or >180 bpm), and those not linked to a KPNC facility (n=153 388) were sequentially excluded, resulting in a total of 2 902 646 ECG tracings in 1 067 749 people.

We then selected subjects who were men or women aged over 35 years on January 1, 2005 (n=863 382 subjects). Of those, we selected a subset of 171 141 with 3 or more ECGs, requiring a spacing of ≥3 months between ECGs. An additional 58 507 subjects (yielding a cohort of 112 634) were excluded for not having ≥3 measures of covariate of interest including body mass index, total cholesterol, high-density lipoprotein (HDL) cholesterol, systolic blood pressure, diastolic blood pressure, and estimated glomerular filtration rate (eGFR) in the ascertainment period (2005–2009), ensuring that the repeated measures of covariates were also at least 3 months apart. Further exclusions were being unknown smoking status (n=187), continuous health-plan disenrollment for >180 days (n=3623), and history of prior CVD, including IHD, cardiac arrest, total stroke, heart failure, ventricular dysrhythmias (n=45 791), and left or right bundle branch block (n=1578). The final study cohort was 61 455 people with an average (SD) number of ECGs of 3.7 (1.1).

QT Measurement and Adjustment for Heart Rate and Secular Trend

All ECGs in the KPNC system were obtained using cardiographs manufactured by Philips Medical Systems (Andover, MA). For this study, we extracted the raw QT and RR measurements that were generated from each 12-lead waveform by the proprietary Philips algorithms (software versions PH07 and PH08), which are described elsewhere. To correct for heart rate, we used the Fridericia correction formula, which significantly improves prediction of 30-day and 1-year mortality compared with the Bazett correction.
observed a gradual upward trend in mean QTc between 2005 and 2012, which was driven by a change in the algorithm used to measure QT (from PH7 to PH8), and this happened at different time points across KPNC facilities. We generated plots of annual mean QTc for each separate facility and determined the year of transition for each facility. Using data for the entire membership (over 1.1 million subjects), we detrended the QTc values during the transition years by fitting a linear time trend, then subtracting off the mean QTc in each year predicted by the linear model and translating the detrended data to the posttransition QTc values by adding the mean QTc of all data in the posttransition years. We also noticed a slight upward trend of mean QTc in the years preceding the transition. We therefore detrended the QTc values during this period using a spline model (restricted cubic splines with 3 internal knots based on percentiles) to allow for nonlinearity.

**Study Covariates and CVD Outcomes**

Demographics, smoking status, body mass index, and systolic and diastolic blood pressure were ascertained from inpatient and outpatient electronic records. Use of antihypertensives and cholesterol-lowering agents were obtained from the health-plan outpatient pharmacy database. Diabetes was determined by linkage with the Kaiser Permanente Division of Research Diabetes Registry. Total cholesterol, HDL cholesterol, and serum creatinine were obtained from the Kaiser Permanente Regional Laboratory Utilization Results System. Non-HDL cholesterol was total cholesterol minus HDL cholesterol. eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration formula. CVD outcomes were based on primary discharge diagnosis or underlying cause of death that occurred between January 1, 2010 and December 31, 2019 (see Table S1 containing the International Classification of Diseases, Ninth and Tenth Revision [ICD-9 and ICD-10] and procedure codes). The CVD outcomes included IHD, cardiac arrest, total stroke, heart failure, ventricular dysrhythmias, all CVD, and total mortality. The study was approved by the Kaiser Foundation Research Institute Institutional Review Board, and the informed consent requirement was waived.

**Statistical Analysis**

For all continuous variables (QTc, body mass index, non-HDL cholesterol, systolic blood pressure, diastolic blood pressure, and eGFR), we generated 3 variables capturing the dynamics over a 5-year period: long-term average, linear change, and fluctuation. Linear change was the slope against time derived from the longitudinal measurements available per subject. Fluctuation was the root mean squared error (RMSE), which represents the residual variability around the overall time trend. To assess bivariate associations among covariates, we computed Pearson correlation coefficients for continuous variables (all were normally distributed) and point biserial correlations between the 3 QTc dynamic variables and categorical variables. We estimated the age-adjusted risk of each CVD outcome per 10,000 person-years in sex-specific tertiles of QTc average, slope, and RMSE using Poisson regression. Time-to-event survival analysis was performed with Cox proportional hazards models. For each person, follow-up was defined as time from the last ECG in the covariate ascertainment period (2005–2009) to incident outcome of interest or censoring at death from any cause, termination of health-plan membership (defined as a consecutive 6-month gap in membership), or end of follow-up in December 31, 2018, whichever occurred first (see Figure 1 for a schematic of study design). The mean (SD) follow-up time was 7.6 (2.6) years, and the maximum was 9.0 years. We fitted minimally adjusted Cox models controlling for age, sex, and race/ethnicity, and then fully adjusted models with additional control for smoking status, diabetes, hypertension, cholesterol-lowering medication, plus average, linear slope, and fluctuation of body mass index, non-HDL cholesterol, systolic blood pressure, diastolic blood pressure, and eGFR, respectively.

We estimated the hazard ratio (HR) and 95% CI for each CVD outcome and total mortality for tertiles 2 and 3 relative to tertile 1 in the case of average and RMSE QTc, and for tertile 1 and 3 relative to tertile 2 in the case of QTc linear slope. To assess linear trends, we fitted another set of models where the main exposures were standardized effects (ie, per 1-SD increment) of continuous QTc average, QTc linear slope, and QTc RMSE, respectively. To evaluate the risks associated with clinically accepted sex-specific thresholds for long QTc (>450 ms in men and >460 ms in women), we fitted 2 supplemental models, one considering any (ie, 1 or more) ECG with long QTc versus no ECG with long QTc and another considering average QTc in the long-QTc range versus average QTc not in the long-QTc range. To allow comparison of strength of independent association with CVD outcomes across static and dynamic QTc measures, we ran 3 separate fully adjusted Cox models series entering the first QTc, the last QTc, and then QTc average. Each of these series of models were adjusted for the same vector of covariates listed above. Because the Bazett correction for QT is more commonly used clinically, we performed a sensitivity analyses of CVD outcomes using the Bazett correction. A 2-tailed P value of 0.05 was considered to indicate statistical significance. All statistical analyses were performed using SAS release 9.13 (SAS Institute, Cary, NC).
RESULTS

The mean (SD) age of the cohort at the last ECG was 63 (12) years (Table 1). The study sample was 60% women and racially/ethnically diverse: 57% White, 9% Black, 12% Asian/Pacific Islander, 14% Hispanic/Latino, and 7% mixed race. For QTc, the mean of the average (SD) was 427 (22) ms, the mean (SD) of the slope was 0.6 (13) ms/y, and the mean (SD) of the RMSE was 15 (12) ms. About 28% of the cohort had at least 1 ECG with long QTc, and 9% had an average QTc in the long-QTc range. By contrast, none had an average QTc in the short-QTc range. About 28% of the cohort had at least 1 ECG with long QTc, and 9% had an average QTc in the long-QTc range. By contrast, none had an average QTc in the short-QTc range (≤300 ms), and 20 unique individuals had 1 ECG with short QTc (≤300 ms, ranging from 251 to 297 ms). Five percent were current smokers, 32% had a diagnosis of diabetes, 83% were on antihypertensive medication, and 67% on cholesterol-lowering drugs.

Table 2 summarizes the intercorrelations among QT variables themselves and with the covariates. The first QTc measure correlated 0.19 with age, 0.14 with sex, 0.46 with the last QTc measure, 0.78 with the average QTc, −0.40 with the QTc linear slope and 0.12 with the QTc RMSE, and −0.14 with the eGFR average. The last QTc measure correlated 0.18 with age, 0.10 with sex, 0.80 with average QTc, 0.12 with QTc RMSE, and −0.15 with the eGFR average. QTc average correlated 0.23 with age, 0.15 with sex, 0.11 with hypertensive medication, 0.19 with QTc RMSE, 0.11 with systolic blood pressure average, 0.10 with systolic blood pressure RMSE, and −0.19 with the eGFR average. QTc RMSE correlated 0.10 with age and 0.12 with the first and last QTc, respectively.

The associations of average QTc with CVD outcomes are summarized in Table 3. In minimally adjusted models, positive significant linear trends were observed for all CVD outcomes and all-cause mortality (all P<0.0001). In the fully adjusted models, tertile 3 (relative to tertile 1) of the average QTc was associated, in order of strength, with cardiac arrest (HR, 1.66), heart failure (HR, 1.62), ventricular dysrhythmias (HR, 1.56), all CVD (HR, 1.31), IHD (HR, 1.28), all-cause mortality (HR, 1.24), and total stroke (HR, 1.18).

The associations of QTc linear slope with CVD outcomes are summarized in Table 4. In minimally adjusted models, significant linear trends were observed for total stroke, heart failure, ventricular dysrhythmias, and all CVD (all P≤0.03). In the fully adjusted models, tertile 3 (relative to tertile 2) of the QTc linear slope was associated, in order of strength, with cardiac arrest (HR, 1.22), ventricular dysrhythmias (HR, 1.12), and total mortality (HR, 1.09), and was not significantly associated with IHD, total stroke, heart failure, or all CVD.

The associations of QTc RMSE with CVD outcomes are summarized in Table 5. In minimally adjusted models, positive significant linear trends were noted for IHD, total stroke, heart failure, ventricular dysrhythmias, all CVD, and all-cause mortality (all P<0.002). In the fully adjusted models, tertile 3 (relative to tertile 1) of the QTc RMSE was associated, in order of strength, with ventricular dysrhythmias (HR, 1.34), heart failure (HR, 1.28), total mortality (HR, 1.20), all CVD (HR, 1.14), total stroke (HR, 1.08), and IHD (HR, 1.07).

Table S2 details the risks associated with having at least 1 ECG with long QTc. The multivariate-adjusted hazard ratios varied from 1.22 for total stroke to 1.84...
for heart failure. Similar association were seen for having an average QTc in the long-QTc range (Table S3).

Figure 2 displays the HR (95% CI) for CVD conditions associated with the upper tertile of the first and the last static-QT measures along with the 3 longitudinal measures (average, linear slope, and RMSE). For IHD, cardiac arrest, all CVD, and ventricular dysrhythmias, the strongest predictor was the average QTc. For heart failure, total stroke, and all-cause mortality, average QTc and the last QTc had similar strengths of association. We also performed a sensitivity analysis using the more commonly used Bazett QT correction for heart rate instead of the Fridericia correction. Results are depicted in Figure S1. For IHD, all CVD, heart failure, and ventricular dysrhythmias, the strongest predictor was the average QTc. For stroke, cardiac arrest, and all-cause mortality, the strongest predictor was the last QTc measure.

DISCUSSION
The association of a static measure of the QT interval with CVD outcomes (including sudden cardiac death) is well established in the literature. However, there are limited data on the relationship of multiple QTc measures with subsequent adverse cardiovascular events. In a recent meta-analysis by Zhang et al with 23 observational studies included, the investigators found consistent associations between prolonged QT interval and increased risk of IHD, cardiovascular and total mortality, as well as sudden cardiac death. The pooled relative risk comparing the highest and lowest categories of QT interval was 1.71 (95% CI, 1.36–2.15) for coronary heart disease, 1.51 (95% CI, 1.29–1.78) for cardiovascular mortality, 1.35 (95% CI, 1.26–1.46) for total mortality, and 1.44 (95% CI, 1.01–2.04) for sudden cardiac death.\(^\text{37}\) Our results (even the analysis of a single static measure) are not directly comparable with the findings of Zhang et al, because of methodological differences, including consideration of nonfatal as well as fatal events, adjustment for a more complete set of longitudinal covariates, and the fact that some of the studies included in the meta-analysis employed higher cutoff points for the highest category of QT length.
The average QTc over a 5-year period was positively correlated with age, female sex, White race, antihypertension medication, and systolic blood pressure average and fluctuation; the average QTc was negatively correlated with long-term average eGFR. Longer QTc intervals with increasing age and in women compared with men is a well-known phenomenon.38–40 The relationship of QTc with impaired kidney function has also been described.41 Park et al reported an association between metabolic syndrome and its components, including blood pressure, with prolonged corrected QTc interval in healthy Korean men and women.42 Several clinical pathologies have been shown to prolong or shorten the QTc interval. In patients with heart failure, an increased brain natriuretic peptide was found to be associated with an increased risk of sudden cardiac death, primarily in patients with a prolonged QTc interval.42 Similarly, QTc has been found to be positively correlated with high-sensitivity C-reactive protein levels and an increased inflammatory burden. Panoulas et al found that patients with rheumatoid arthritis and a higher inflammatory burden had a prolonged QTc

|                      | First QTc | Last QTc | QTc average | QTc linear slope | QTc RMSE |
|----------------------|-----------|----------|-------------|-----------------|---------|
|                      | $r$       | $P$ value| $r$         | $P$ value       | $r$     |
| Age                  | 0.19      | 0.0000   | 0.18        | 0.0000          | 0.23    |
| Sex                  | 0.14      | <0.0001  | 0.10        | <0.0001         | 0.15    |
| Race/ethnicity       |           |          |             |                 |         |
| White                | 0.06      | <0.0001  | 0.04        | <0.0001         | 0.07    |
| Black                | −0.05     | <0.0001  | −0.02       | <0.0001         | −0.04   |
| Asian and Pacific Islander | −0.02     | <0.0001  | −0.02       | <0.0001         | −0.03   |
| Latino               | −0.03     | <0.0001  | −0.02       | <0.0001         | −0.03   |
| Native American      | −0.01     | 0.06     | −0.01       | 0.007           | −0.01   |
| Mixed                | 0.002     | 0.71     | 0.003       | 0.45            | 0.002   |
| Never smoking        | 0.0006    | 0.88     | −0.0007     | 0.86            | 0.002   |
| Former smoking       | 0.01      | 0.12     | 0.01        | 0.07            | 0.01    |
| Current smoking      | −0.02     | <0.0001  | −0.01       | 0.002           | −0.02   |
| Diabetes             | −0.04     | <0.0001  | −0.01       | <0.0001         | −0.01   |
| Hypertension medication | 0.08     | <0.0001  | 0.09        | <0.0001         | 0.11    |
| Cholesterol-lowering drugs | 0.04    | <0.0001  | 0.05        | <0.0001         | 0.05    |
| First QTc            |           |          | NA          | NA              |         |
| Last QTc             | 0.46      | <0.0001  | NA          | NA              | 0.80    |
| QTc average          | 0.78      | <0.0001  | 0.80        | <0.0001         | ...     |
| QTc linear slope     | −0.40     | <0.0001  | 0.46        | <0.0001         | 0.04    |
| QTc RMSE             | 0.12      | <0.0001  | 0.12        | <0.0001         | 0.19    |
| BMI                   | −0.03     | <0.0001  | −0.02       | <0.0001         | −0.03   |
| BMI linear slope     | −0.03     | <0.0001  | −0.01       | <0.0001         | −0.02   |
| BMI RMSE             | 0.01      | 0.007    | 0.02        | <0.0001         | 0.02    |
| Non-HDL cholesterol average | −0.05    | <0.0001  | −0.05       | <0.0001         | −0.06   |
| Non-HDL cholesterol linear slope | −0.02    | 0.0002  | −0.01       | 0.04            | −0.01   |
| Non-HDL cholesterol RMSE | −0.01    | 0.0007  | −0.01       | 0.04            | −0.01   |
| SBP average          | 0.08      | <0.0001  | 0.09        | <0.0001         | 0.11    |
| SBP linear slope     | −0.004    | 0.27     | 0.004       | 0.34            | −0.002  |
| SBP RMSE             | 0.07      | <0.0001  | 0.09        | <0.0001         | 0.10    |
| DBP average          | −0.08     | <0.0001  | −0.07       | <0.0001         | −0.09   |
| DBP linear slope     | 0.005     | 0.22     | 0.0008      | 0.84            | 0.002   |
| DBP RMSE             | 0.02      | <0.0001  | 0.03        | <0.0001         | 0.03    |
| eGFR average         | −0.14     | <0.0001  | −0.15       | 0.0000          | −0.19   |
| eGFR linear slope    | −0.0002   | 0.96     | −0.03       | <0.0001         | −0.02   |
| eGFR RMSE            | −0.01     | 0.11     | −0.003      | 0.49            | −0.005  |

BMI indicates body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; QTc, corrected QT; RMSE, root mean squared error; and SBP, systolic blood pressure.
Table 3. Association of QTc Average With CVD Outcomes

| Outcomes               | Tertile 1, n=20 485 | Tertile 2, n=20 485 | Tertile 3, n=20 485 | 1-SD increment |  
|------------------------|---------------------|---------------------|---------------------|----------------|  
|                        | No. of events       | AAR per 10 000 person-years | MaHR (95% CI) | No. of events | AAR per 10 000 person-years | MaHR (95% CI) | No. of events | AAR per 10 000 person-years | MaHR (95% CI) | MaHR (95% CI) | FaHR (95% CI) | FaHR (95% CI) | P value trend |  
| IHD                    | 3629                | 237.6               | 1                   | 3962           | 236.7               | 1.10 (1.05–1.15) | 4866           | 288.9               | 1.40 (1.34–1.46) | 1.16 (1.14–1.18) | <0.0001 |  
| Cardiac arrest         | 333                 | 20.2                | 1                   | 414            | 23.6                | 1.31 (1.14–1.52) | 593            | 32.6                | 1.81 (1.57–2.08) | 1.28 (1.21–1.34) | <0.0001 |  
| Total stroke           | 3067                | 196.4               | 1                   | 3486           | 208.4               | 1.10 (1.05–1.16) | 4039           | 228.1               | 1.24 (1.18–1.30) | 1.09 (1.07–1.11) | <0.0001 |  
| Heart failure          | 3203                | 194.6               | 1                   | 3850           | 213.9               | 1.18 (1.13–1.24) | 5093           | 305.0               | 1.77 (1.70–1.86) | 1.31 (1.29–1.33) | <0.0001 |  
| Ventricular dysrhythmias | 712              | 43.6                | 1                   | 810            | 47.3                | 1.21 (1.09–1.34) | 1130           | 64.5                | 1.68 (1.52–1.85) | 1.28 (1.23–1.32) | <0.0001 |  
| A1 CVD                 | 7465                | 531.1               | 1                   | 8206           | 549.7               | 1.11 (1.08–1.15) | 10 290         | 672.6               | 1.41 (1.27–1.35) | 1.17 (1.15–1.18) | <0.0001 |  
| All-cause mortality    | 4917                | 263.6               | 1                   | 5671           | 263.4               | 1.07 (1.03–1.11) | 7776           | 31.9                | 1.30 (1.26–1.36) | 1.12 (1.11–1.14) | <0.0001 |  

MaHRs are adjusted for age, sex, race/ethnicity, QTc linear slope, and QTc RMSE. FaHRs are adjusted for age, sex, race/ethnicity, QTc linear slope, and QTc RMSE, smoking status, diabetes, hypertension medication, cholesterol-lowering drugs, BMI (average, linear slope, RMSE), non-HDL cholesterol (average, linear slope, RMSE), SBP (average, linear slope, RMSE), DBP (average, linear slope, RMSE), and eGFR (average, linear slope, RMSE). AAR indicates age-adjusted rate; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FaHR, fully adjusted hazard ratio; HDL, high-density lipoprotein; IHD, ischemic heart disease; MaHR, minimally adjusted hazard ratio; QTc, corrected QT; RMSE, root mean squared error; and SBP, systolic blood pressure.
Table 4. Association of QTc Linear Slope With CVD Outcomes

| Outcomes               | Tertile 1, n=20 485 | Tertile 2, n=20 485 | Tertile 3, n=20 485 | 1-SD increment |
|------------------------|---------------------|---------------------|---------------------|----------------|
|                        | No. of events       | AAR per 10 000     | MaHR (95% CI)       | FaHR (95% CI)  |
|                        |                     | person-years       |                     |                |
|                        |                     | 1                   |                     |                |
|                        |                     | 1                   |                     |                |
|                        |                     | 1                   |                     |                |
|                        |                     | 1                   |                     |                |
| IHD                    | 4059                | 249.2               | 0.97 (0.93–1.01)    | 0.97 (0.93–1.02) |
|                        |                     | 0.95 (0.91–1.00)    | 0.94 (0.90–0.99)    | 1.00 (0.98–1.02) |
| Cardiac arrest         | 449                 | 25.5                | 1.20 (1.04–1.37)    | 1.31 (1.15–1.50) |
|                        |                     | 1.16 (1.01–1.33)    | 1.22 (1.07–1.39)    | 1.02 (0.97–1.07) |
| Total stroke           | 3492                | 207.3               | 0.99 (0.95–1.04)    | 1.03 (0.99–1.08) |
|                        |                     | 0.98 (0.94–1.03)    | 1.00 (0.96–1.05)    | 1.02 (1.00–1.03) |
| Heart failure          | 4210                | 229.3               | 0.99 (0.95–1.04)    | 1.10 (1.05–1.14) |
|                        |                     | 0.96 (0.92–1.00)    | 1.04 (1.00–1.08)    | 1.02 (1.01–1.04) |
| Ventricular dysrhythmias| 854                | 49.7                | 1.03 (0.94–1.14)    | 1.15 (1.05–1.27) |
|                        |                     | 1.01 (0.92–1.12)    | 1.12 (1.02–1.23)    | 1.03 (1.00–1.07) |
| All CVD                | 8561                | 574.4               | 1.00 (0.97–1.03)    | 1.03 (1.00–1.06) |
|                        |                     | 0.98 (0.95–1.01)    | 1.00 (0.97–1.03)    | 1.01 (1.00–1.02) |
| All-cause mortality    | 6246                | 282.6               | 1.10 (1.06–1.14)    | 1.15 (1.11–1.19) |
|                        |                     | 1.06 (1.02–1.10)    | 1.09 (1.05–1.13)    | 1.01 (0.99–1.02) |

MaHRs are adjusted for age, sex, race/ethnicity, QTc average, and QTc RMSE. FaHRs are adjusted for age, sex, race/ethnicity, QTc average and QTc RMSE, smoking status, diabetes, hypertension medication, cholesterol-lowering drugs, BMI (average, linear slope, RMSE), non-HDL cholesterol (average, linear slope, RMSE), SBP (average, linear slope, RMSE), DBP (average, linear slope, RMSE), and eGFR (average, linear slope, RMSE). AAR indicates age-adjusted rate; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FaHR, fully adjusted hazard ratio; HDL, high-density lipoprotein; IHD, ischemic heart disease; MaHR, minimally adjusted hazard ratio; QTc, corrected QT; RMSE, root mean squared error; and SBP, systolic blood pressure.
### Table 5. Association of QTc RMSE With CVD Outcomes

| Outcomes               | Tertile 1, n=20 485 | Tertile 2, n=20 485 | Tertile 3, n=20 485 | 1-SD increment | P value trend |
|------------------------|----------------------|----------------------|----------------------|----------------|--------------|
|                        | No. of events | AAR per 10 000 person-years | MaHR (95% CI) | FaHR (95% CI) | No. of events | AAR per 10 000 person-years | MaHR (95% CI) | FaHR (95% CI) | No. of events | AAR per 10 000 person-years | MaHR (95% CI) | FaHR (95% CI) | |
| IHD                    | 3864      | 235.8                 | 1 4170 259.4 | 1.11 (1.06–1.16) | 4323      | 267.9                 | 1.12 (1.07–1.17) | 1.03 (1.01–1.04) | 0.002 | 1.07 (1.02–1.11) | 1.01 (1.00–1.03) | 0.12 |
| Cardiac arrest         | 393       | 22.2                  | 1 438 25.1 | 1.10 (0.96–1.26) | 509       | 29.2                  | 1.18 (1.04–1.35) | 1.04 (0.99–1.09) | 0.09 | 1.08 (0.95–1.24) | 1.02 (0.97–1.07) | 0.51 |
| Total stroke           | 3304      | 196.1                 | 1 3589 216.3 | 1.11 (1.06–1.16) | 3699      | 220.9                 | 1.13 (1.08–1.18) | 1.03 (1.01–1.05) | 0.0009 | 1.08 (1.03–1.13) | 1.02 (1.00–1.04) | 0.08 |
| Heart failure          | 3665      | 202.5                 | 1 4193 232.2 | 1.17 (1.12–1.22) | 5104      | 279.0                 | 1.37 (1.31–1.43) | 1.08 (1.07–1.10) | <0.0001 | 1.28 (1.23–1.34) | 1.07 (1.05–1.09) | <0.0001 |
| Ventricular dysrythmias| 743       | 42.9                  | 1 852 50.0 | 1.16 (1.06–1.26) | 1057      | 62.8                  | 1.40 (1.27–1.53) | 1.11 (1.07–1.14) | <0.0001 | 1.34 (1.22–1.47) | 1.09 (1.06–1.13) | <0.0001 |
| All CVD                | 7944      | 527.2                 | 1 8652 588.9 | 1.13 (1.09–1.16) | 9065      | 637.4                 | 1.20 (1.16–1.23) | 1.06 (1.05–1.07) | <0.0001 | 1.14 (1.11–1.18) | 1.04 (1.03–1.06) | <0.0001 |
| All-cause mortality    | 5175      | 243.7                 | 1 5899 274.1 | 1.13 (1.08–1.17) | 7290      | 322.7                 | 1.31 (1.27–1.36) | 1.10 (1.09–1.11) | <0.0001 | 1.20 (1.16–1.25) | 1.07 (1.06–1.09) | <0.0001 |

MaHRs are adjusted for age, sex, race/ethnicity, QTc average and QTc slope. FaHRs are adjusted for age, sex, race/ethnicity, QTc average and QTc slope, smoking status, diabetes, hypertension medication, cholesterol-lowering drugs, BMI (average, linear slope, RMSE), non-HDL cholesterol (average, linear slope, RMSE), SBP (average, linear slope, RMSE), DBP (average, linear slope, RMSE), and eGFR (average, linear slope, RMSE). AAR indicates age-adjusted rate; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FaHR, fully adjusted hazard ratio; HDL, high-density lipoprotein; IHD, ischemic heart disease; MaHR, minimally adjusted hazard ratio; QTc, corrected QT; RMSE, root mean squared error; and SBP, systolic blood pressure.
interval and increased rates of sudden cardiac death; a 50-ms increase in QTc was found to be associated with a doubling of the hazard for all-cause mortality in patients with rheumatoid arthritis.\textsuperscript{17}

Our results demonstrate that long-term average QTc was the better predictor of IHD, cardiac arrest, all CVD, and ventricular dysrhythmias, and that average QTc and the last QTc measure were equally predictive in the case of heart failure, total stroke, and all-cause mortality. The QTc linear slope conveyed independent predictive ability for cardiac arrest, ventricular dysrhythmias, and all-cause mortality, whereas the QTc RMSE remained independently associated with IHD, total stroke, heart failure, ventricular dysrhythmias, all CVD, and all-cause mortality.

Because of the accessibility and cost-effective nature of a 12-lead ECG, this is often the initial diagnostic test performed in patients presenting to the inpatient or outpatient setting with chest pain or shortness of breath. By using data over several ECGs, rather than a single data point, and understanding the predictive ability of QTc change and variability over time, clinicians will be better equipped to risk stratify patients for CVD outcomes. This may aid in determination of which patient cohorts would benefit from longer-term rhythm monitoring and aid in primary and secondary CVD prevention recommendations. A simple calculator could be embedded in the electronic health record to estimate the patient’s long-term QTc average, slope, and RMSE. Further research is needed to determine the extent to which the associations of QTc change and fluctuation with CVD outcomes are attributable to variations in medication compliance with drugs known to alter the QT interval.

Within-person QTc variability has been described in relation to brief high-intensity intermittent exercise\textsuperscript{43} and with postural changes\textsuperscript{44}; this is thought to be secondary to the effects of the autonomic nervous system.\textsuperscript{45} Thus, autonomic dysregulation may be the substrate of greater QTc variability and enhanced predisposition to ventricular dysrhythmias and heart failure.

The strengths of our study include (1) the large sample size and up to 9 years of cohort follow-up; (2) the racial and ethnic diversity of the sample, thus increasing generalizability; (3) the source of data reflecting a real-world health care setting; and (4) the availability of longitudinal information on QT length and covariates, thus allowing assessment of within-person change and fluctuation in QTc and adjustment for dynamic changes in risk factors. However, the present study also has several limitations. First, KPNC does not currently offer ECGs at annual physicals; therefore, the ECGs were obtained for cause as part of routine medical care. Second, although we adjusted for traditional risk factor level, change, and fluctuation, there may be unmeasured confounding variables that bias the results including electrolyte levels, medication use, structural heart disease, or clinical pathologies that are known to alter the QT interval. Third, we cannot rule out reverse causality, for example, onset of heart failure leading to prolonged QT. Fourth, we did not have data on natriuretic peptides (brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide) or high-sensitivity
C-reactive protein, both important risk markers of heart failure. Fifth, we did not have information on left ventricular ejection fraction, so distinguishing types of heart failure was not possible. Sixth, we did not adjust for other clinical pathologies known to influence the QT interval (hypothyroidism, anorexia nervosa). Lastly, we did not attempt to capture sudden cardiac death in our population-based setting. We believe the results of our study will enable clinicians to better interpret the meaning of serial QTc interval measures, help predict long-term CVD risk, and enable proper QTc monitoring in high-risk populations.

In particular, our findings demonstrate the potential usefulness of monitoring within-person change and fluctuation in QTc over time as new markers to predict increased risk of CVD outcomes. These are clinically relevant results because ECG is a routine, widely available, noninvasive, and inexpensive clinical test.

REFERENCES

1. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J. 1993;70:43–48. doi: 10.1136/hrt.70.1.43
2. Forssell G, Ornstein E. QT prolongation and ventricular fibrillation in acute myocardial infarction. Acta Med Scand. 1981;210:309–311. doi: 10.1111/j.0965-6801.1981.tb09821.x
3. Moller M. QT interval in relation to ventricular arrhythmias and sudden cardiac death in postmyocardial infarction patients. Acta Med Scand. 1981;210:73–77. doi: 10.1111/j.0965-6801.1981.tb09778.x
4. Puddu PE, Bourassa MG. Prediction of sudden death from QTc interval prolongation in patients with chronic ischemic heart disease. J Electrocardiol. 1986;19:203–211. doi: 10.1016/S0022-0736(86)80030-9
5. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978;57:1074–1077. doi: 10.1161/01.CIR.57.6.1074
6. Taylor GJ, Crampton RS, Gibson RS, Stebbins PT, Waldman MT, Beller GA. Prolonged QT interval at onset of acute myocardial infarction in predicting early phase ventricular tachycardia. Am Heart J. 1981;102:16–24. doi: 10.1016/0002-8703(81)90407-5
7. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbabini F, Goulene K, Inoliva R, Mannarino S, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120:1761–1767. doi: 10.1161/CIRCULATIONAHA.109.866250
8. Beinart R, Zhang Y, Lima JA, Bluemke DA, Soliman EZ, Heckbert SR, Permanente, Oakland, CA (M.L., C.L., E.J., C.I.); and Institute for Human Center, San Francisco, CA (N.M., J.G.Z.); Division of Research, Kaiser Department of Cardiology, Kaiser Permanente San Francisco Medical
9. Cupa J, Strebelt I, Badertscher P, Alabéricher T, Twerenbold R, Schumacher L, Boeddinghaus J, Nestesteiberger T, Maechier P, Kozhuharov N, et al. Diagnostic and prognostic value of QRS duration and QTc interval in patients with suspected myocardial infarction. Cardiol J. 2018;25:601–610. doi: 10.5603/CJ.a2018.0033
10. Jimenez-Candil J, Gonzalez IC, Gonzalez Matas JM, Albarran C, Pabon P, Morinigo JL, Ledesma C, Martin F, Diego M, Martin-Luengo C. Short- and long-term prognostic value of the corrected QT interval in the non-ST-elevation acute coronary syndrome. J Electrocardiol. 2007;40:180–187. doi: 10.1016/j.jelectrocard.2006.10.006
11. Juliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN. QRS duration and mortality in patients with congestive heart failure. Am Heart J. 2002;143:1085–1091. doi: 10.1067/mhj.2002.122516
12. Brooksby P, Batin PD, Nolan J, Lindsay SJ, Andrews R, Mullen M, Baig W, Flapan AD, Prescott RJ, Neilson J, et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-HEART). Eur Heart J. 1999;20:1335–1341. doi: 10.1053/eurh.1999.1542
13. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovanecvic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation. 2003;107:1764–1769. doi: 10.1161/01.CIR.0000057980.84624.95
14. Hage FG, de Mattos AM, Khamash H, Mehta S, Warnock D, Iskandrian AE. QT prolongation is an independent predictor of mortality in end-stage renal disease. Clin Cardiol. 2010;33:361–366. doi: 10.1002/clc.20768
15. Cardoso CR, Salles GF, Deccakhe W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications. 2003;17:169–178. doi: 10.1016/S1056-8727(02)00206-4
16. Okarinen L, Nieminen MS, Vitasalo M, Toivonen L, Wachtell K, Papademetriou V, Jern S, Dahlolf B, Devereux RB, Okin PM. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE Study, The Losartan Intervention For Endpoint Reduction, J Hypertens. 2001;19:1883–1891. doi: 10.1097/00015385.200110000-00025
17. Panoulas VF, Toms TE, Douglas KM, Sandoo A, Metios GS, Stavropoulos-Kalinoglou A, Kitas GD. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology (Oxford). 2019;74:53–58. doi: 10.1093/rheumatology/kez338
18. Patel SI, Ackerman MJ, Shamoun FE, Geske JB, Dollar VH, Cha SS, Bos JM, Lester SJ. QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy. Acta Cardiol. 2019;74:53–58. doi: 10.1007/s11519-018-04095-4
19. Reussner A, Blum S, Aeschbacher S, Eggimann L, Ammann P, Erne P, Moschovitis G, Di Valentino M, Shah D, Schlapper J, et al. QT interval, cardiovascular events and mortality in patients with atrial fibrillation. Int J Cardiol. 2018;252:101–105. doi: 10.1016/j.ijcard.2017.11.078
20. Ziberman-Itskovich S, Rahamim E, Tziporin-Havatinsky F, Ziv-Baran T, Golik A, Zaidenstein R. QT prolongation and death in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease is not related to electrolyte disorders. Int J Chron Obstruct Pulmon Dis. 2019;14:1053–1061. doi: 10.2147/COPD.S196428

ARTICLE INFORMATION

Received February 16, 2021; accepted July 20, 2021.

Affiliations

Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA (N.M., J.G.Z.); Division of Research, Kaiser Permanente, Oakland, CA (M.L., C.L., E.J., C.I.); and Institute for Human Genetics, University of California, San Francisco, CA (N.R., T.H., A.O.-O.).

Sources of Funding

This work was supported by National Heart, Lung and Blood Institute, award: RO1HL140924 (Principal Investigator, Carlos Iribarren).

Disclosures

None.

Supplementary Material

Tables S1–S3

Figure S1

J Am Heart Assoc. 2021;10:e018513. DOI: 10.1161/JAHA.120.018513

QT Interval Dynamics and Cardiovascular Outcomes
21. Dekker JM, Schouten EG, Klootwijk P, Pool J, Kromhout D. Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. Circulation. 1994;90:779–785. doi: 10.1161/01.CIR.90.2.779

22. Goldberg RJ, Bengtson J, Chen ZY, Anderson KM, Locati E, Levy D. Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). Am J Cardiol. 1991;67:55–56. doi: 10.1016/0002-9149(91)90099-7

23. Karjalainen J, Reunanen A, Ristola P, Vitasalo M. QT interval as a cardiac risk factor in a middle aged population. Heart. 1997;77:543–548. doi: 10.1136/hrt.77.6.543

24. Maebuchi D, Arima H, Doi Y, Ninomiya T, Yonemoto K, Tanizaki Y, Kubo M, Hata J, Matsumura K, Iida M, et al. QT interval prolongation and the risks of stroke and coronary heart disease in a general Japanese population: the Hisayama study. Hypertens Res. 2010;33:916–921. doi: 10.1038/hr.2010.88

25. Rautaharju PM, Kooperberg C, Larson JC, LaCroix A. Electrocardiographic predictors of incident congestive heart failure and all-cause mortality in postmenopausal women: the Women’s Health Initiative. Circulation. 2006;113:481–489. doi: 10.1161/CIRCULATIONAHA.105.537415

26. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med. 2003;115:689–694. doi: 10.1016/j.amjmed.2003.07.014

27. Zhang Y, Post WS, Dalal D, Blasco-Colmenares E, Tomasselli GF, Guallar E. QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2011;171:1727–1733. doi: 10.1001/archinternmed.2011.433

28. Nielsen JB, Graff C, Rasmussen PV, Pietersen A, Lind B, Olesen MS, Nielsen JO. QT interval as a cardiovascular risk factor in a middle-aged population: the Hisayama study. Hypertens Res. 2010;33:916–921. doi: 10.1038/hr.2010.88

29. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med. 2003;115:689–694. doi: 10.1016/j.amjmed.2003.07.014

30. Rautaharju PM, Kooperberg C, Larson JC, LaCroix A. Electrocardiographic predictors of incident congestive heart failure and all-cause mortality in postmenopausal women: the Women’s Health Initiative. Circulation. 2006;113:481–489. doi: 10.1161/CIRCULATIONAHA.105.537415

31. Kligfield P, Hancock EW, Helfenbein ED, Dawson EJ, Cook MA, Lindauer TJ, Prasad A, Stang P. Short QT in a cohort of 1.7 million persons: validation and application of a new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006

32. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al.; CKD-EPI. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006

33. Selby JV, Schouten EG, Klootwijk P, Pool J, Kromhout D. Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. Circulation. 1994;90:779–785. doi: 10.1161/01.CIR.90.2.779

34. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al.; CKD-EPI. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006

35. Lefondre K, Abrahamowicz M, Regeasse A, Hawker GA, Badley EM, McCusker J, Belzile E. Statistical measures were proposed for identifying longitudinal patterns of change in quantitative health indicators. J Clin Epidemiol. 2004;57:1049–1082. doi: 10.1016/j.jclinepi.2004.02.012

36. Moss AJ. Long QT syndrome. JAMA. 2003;289:2041–2044. doi: 10.1001/jama.289.16.2041

37. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomasselli GF, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology. 2011;22:660–670. doi: 10.1097/EDN.0b013e31822576bb

38. Heemskerk CPM, Pereboom M, van Stralen K, Berger FA, van den Bermt P, Kuipper AFM, van der Hoeven RTM, Mantel-Teeuwisse AK, Becker ML. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018;74:183–191. doi: 10.1007/s00228-017-2381-5

39. Vink AS, Clar SB, Wilde AAM, Blom NA. Effect of age and gender on the QTc-interval in healthy individuals and patients with long-QT syndrome. Trends Cardiovasc Med. 2018;28:64–75. doi: 10.1016/j.tcm.2017.07.012

40. Rabin SW, Cheng XJ, Thompson DJ. Detailed analysis of the impact of age on the QT interval. J Geriatr Cardiol. 2016;13:740–748. doi: 10.11909/j.issn.1671-5411.2016.09.013

41. Liu P, Han D, Sun X, Tan H, Wang Z, Liu C, Zhang Y, Li B, Sun C, Shi R, et al. Prevalence and risk factors of acquired long QT syndrome in hospitalized patients with chronic kidney disease. J Investig Med. 2019;67:289–294. doi: 10.1136/jim-2019-000798

42. Park B, Lee YJ. Metabolic syndrome and its components as risk factors for prolonged corrected QT interval in apparently healthy Korean men and women. J Clin Lipidol. 2018;12:1298–1304. doi: 10.1016/j.jcll.2018.07.004

43. Nie J, Shi Q, Kong Z, Lao CK, Zhang H, Tong TK. QTc interval prolongation during recovery from brief high-intensity intermittent exercise in obese adults. Herz. 2020;45:67–71. doi: 10.1007/s00059-019-4808-5

44. Dione A, Fournier A, Daadah N, Abrams D, Khairy P, Abarb S. Dynamic QT interval changes from supine to standing in healthy children. J Geriatr Cardiol. 2017;14:33–44. doi: 10.11909/j.issn.1671-5411.2016.09.013

45. Winter J, Tipton MJ, Shattock MJ. Autonomic conflict exacerbates QT associated ventricular arrhythmias. J Mol Cell Cardiol. 2018;113:145–154. doi: 10.1016/j.yjmcc.2018.02.001

46. El-Sherif N, Turitto G, Boujdia M. Acquired long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol. 2018;41:414–421. doi: 10.1111/jpe.13296

47. Jauregui-Garrido B, Jauregui-Lobera I. Sudden death in eating disorders. Vasc Health Risk Manag. 2012;8:91–98. doi: 10.2147/VHRM.S28652

48. Iribarren C, Jacob S, Jacobs DR Jr, Luepker RV. Validation of death certificate diagnosis of out-of-hospital sudden cardiac death. Am J Cardiol. 1998;82:50–53. doi: 10.1016/S0002-9149(98)00204-9

49. Irbinat C, Round AD, Peng JA, Lu M, Klatsky AL, Zoroff JG, Holve TJ, Prasad A, Stang P. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann Noninvasive Electrocardiol. 2014;19:490–500. doi: 10.1111/anec.12157
Table S1. Ascertainment of Cardiovascular Endpoints and Exclusionary Conditions.

| Condition                                      | Primary hospital discharge code or underlying cause of death ICD-9 code | Primary hospital discharge code or underlying cause of death ICD-10* code | CPT4 Code(s)                      | ICD-10 procedure Codes (PCS)       |
|------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------|-----------------------------------|
| Pacemaker insertion                            | 37.6, 37.7, 37.8, 37.9 (ICD-9 procedure codes)                        |                                                                         | 33217, 33218, 33220, 33221, 33222, 33223, 33224, 33225, 33226, 33227, 33228, 33229, 33230, 33231, 33233, 33234, 33235, 33236, 33237, 33238, 33240, 33244, 33249, 33262, 33263, 33264, 33270, 33271, 33272, 33273 | 0JH636Z, 02H63JZ 02HK3JZ, 3E0132A |
| Acute myocardial infarction (AMI)               | 410.x                                                                  | 121.x, 122.x                                                            | NA                                |                                   |
| Angina pectoris                                 | 411.x, 413.x                                                           |                                                                         | NA                                |                                   |
| Coronary atherosclerosis due to calcified coronary lesion | 414.4                                                                | 125.84                                                                 | NA                                |                                   |
| Other forms of ischemic heart disease           | 414.x                                                                  | 125.x                                                                   | NA                                |                                   |
| Coronary artery bypass surgery (CABG)           | 36.10, 36.11, 36.12, 36.13, 36.14, 36.15, 36.16, 36.17, 36.19, 36.03  |                                                                         | 33510, 33511, 33512, 33513, 33514, 33515, 33516, 33517, 33518, 33519, 33521, 33522, 33523, 33530, 33533, 33534, 33535, 33536 | 0212029, 021009W  |
| Percutaneous coronary intervention (PCI) with or without intra-coronary stenting | 36.01, 36.02, 36.05, 36.06, 36.07, 36.09                            |                                                                         | NA                                | 92980, 92981, 92982, 92984, 92995, 92996, 92975, 92977 | 0270346, 02703ZZ, 02703DZ, 02CO3ZZ |
| Cardiac arrest                                  | 427.5                                                                  |                                                                         | I46.2                             |                                   |
| Hemorrhagic stroke                              | 430.x, 431.x, 432.1, 432.9                                              |                                                                         | I60.x, I61.x, I62.x               | NA                                |
| Ischemic stroke                                 | 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 436.x | I63.x                                                                   | NA                                |                                   |
| Heart failure (HF)                              | 426.x, 402.01, 402.11, 402.91, 398.91, 404.01, 404.03, 404.11, 404.12, 404.13, 404.91, 404.93 | I50.x, I09.81, I11.0, I13.0, I13.2, I13.11                          | NA                                |                                   |
| Ventricular dysrhythmias                        | 427.1, 427.2, 427.41, 427.42                                              |                                                                         | I47.2, I47.9, I49.01, I49.02      |                                   |
| Right bundle branch block                       | 426.4                                                                  |                                                                         | I44.10                             |                                   |
| Left bundle branch block                        | 426.3                                                                  |                                                                         | I44.7                              |                                   |

CABG + PCI = Revascularization Procedures (RP)
AMI + Angina pectoris + other forms of ischemic heart disease + RP = Ischemic Heart Disease (IHD)
Ischemic Stroke + Hemorrhagic Stroke = Total Stroke (TS)
CHD + TS + HF = Total CVD
NA: not applicable
Table S2. Association of one or more QTc in the long QT range (any ECG) with CVD outcomes.

| Outcomes                  | QTc ≤ 450 ms in men or ≤ 460 ms in women (n=43,431) | QTc > 450 ms in men or > 460 ms in women (n=18,024) |
|---------------------------|-----------------------------------------------------|--------------------------------------------------|
|                           | Num events | AAR per 10,000 person-years | MaHR (95% CI) FaHR (95% CI) | Num events | AAR per 10,000 person-years | MaHR (95% CI) FaHR (95% CI) |
| IHD                       | 7,811      | 229.8                       | 1 | 4,546 | 317.9                       | 1.39 (1.34, 1.45) |
| Cardiac arrest            | 750        | 20.5                        | 1 | 590   | 38.1                        | 1.76 (1.56, 1.98) |
| Total Stroke              | 7,002      | 201.2                       | 1 | 3,590 | 235.8                       | 1.22 (1.17, 1.27) |
| Heart failure             | 7,262      | 196.0                       | 1 | 5,700 | 345.2                       | 1.84 (1.77, 1.91) |
| Ventricular dysrhythmias  | 1,509      | 42.0                        | 1 | 1,143 | 77.1                        | 1.72 (1.58, 1.87) |
| All CVD                   | 16,405     | 525.0                       | 1 | 9,556 | 739.4                       | 1.43 (1.39, 1.47) |
| All-cause mortality       | 10,811     | 250.8                       | 1 | 7,553 | 353.2                       | 1.38 (1.34, 1.43) |

IHD: ischemic heart disease; CVD: cardiovascular disease; AAA: age-adjusted rate; MaHR: minimally-adjusted hazard ratios; FaHR: fully-adjusted-adjusted hazard ratios; RMSE: Root mean square error; BMI: body mass index; HDL: high-density lipoprotein; GFR: glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MaHR are adjusted for age, sex, race/ethnicity, QTc slope and QTc RMSE; FaHR are adjusted for age, sex, race/ethnicity, QTc slope and QTc RMSE, smoking status, diabetes, hypertension medication, cholesterol lowering drugs, BMI (average, linear slope, RMSE), non-HDL cholesterol (average, linear slope, RMSE), SBP (average, linear slope, RMSE), SBP (average, linear slope, RMSE) and e-GFR (average, linear slope, RMSE).
### Table S3. Association of average QTc in the long QT range (by average) with CVD outcomes.

| Outcomes          | QTc ≤ 450 ms in men or ≤ 460 ms in women (n=55,510) | QTc > 450 ms in men or > 460 ms in women (n=5,945) |
|-------------------|---------------------------------------------------|---------------------------------------------------|
|                   | Num events | AAR per 10,000 person-years | MaHR (95% CI) | FaHR (95% CI) | Num events | AAR per 10,000 person-years | MaHR (95% CI) | FaHR (95% CI) |
| IHD               | 10,621     | 243.7 | 1 | 1,736 | 361.0 | 1.44 (1.37, 1.52) | 1.44 (1.37, 1.52) |
| Cardiac arrest    | 1,095      | 23.3  | 1 | 245  | 46.5  | 1.79 (1.55, 2.07) | 1.79 (1.55, 2.07) |
| Total Stroke      | 9,360      | 208.5 | 1 | 1,232 | 234.7 | 1.17 (1.10, 1.25) | 1.17 (1.10, 1.25) |
| Heart failure     | 10,630     | 220.8 | 1 | 2,332 | 405.1 | 1.87 (1.79, 1.96) | 1.87 (1.79, 1.96) |
| Ventricular dysrhythmias | 2,174 | 47.3  | 1 | 478  | 96.1  | 1.85 (1.67, 2.05) | 1.85 (1.67, 2.05) |
| All CVD           | 22,408     | 561.1 | 1 | 3,553 | 816.1 | 1.45 (1.40, 1.50) | 1.45 (1.40, 1.50) |
| All cause mortality | 15,501    | 270.6 | 1 | 2,863 | 368.4 | 1.32 (1.27, 1.38) | 1.32 (1.27, 1.38) |

IHD: ischemic heart disease; CVD: cardiovascular disease; AAA: age-adjusted rate; MaHR: minimally-adjusted hazard ratios; FaHR: fully-adjusted-adjusted hazard ratios; RMSE: Root mean square error; BMI: body mass index; HDL: high-density lipoprotein; GFR: glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MaHR are adjusted for age, sex, race/ethnicity, QTc slope and QTc RMSE; FaHR are adjusted for age, sex, race/ethnicity, QTc slope and QTc RMSE, smoking status, diabetes, hypertension medication, cholesterol lowering drugs, BMI (average, linear slope, RMSE), non-HDL cholesterol (average, linear slope, RMSE), SBP (average, linear slope, RMSE), SBP (average, linear slope, RMSE) and e-GFR (average, linear slope, RMSE).
Figure S1. Comparison of Strength of Association for Different QTc Measures Using Bazett's heart rate correction (n=59,540).

*vs. tertile 1 for first, average and RMSE and tertile 2 for slope